In this context, studies of Gong et al. (2016) found that genetic polymorphisms of well-characterized lncRNAs such as CCAT2, HOTAIR and MALAT1 were significantly associated with lung cancer susceptibility and platinum-based chemotherapy response, indicating that they might function as clinical biomarkers [75]. This evidence concerns the gene MALAT1 and lung cancer.